Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leuk Lymphoma. 2019 07; 60(7):1693-1696.
View in:
PubMed
subject areas
Adult
Aged
Antineoplastic Agents, Immunological
Cord Blood Stem Cell Transplantation
Epstein-Barr Virus Infections
Female
Follow-Up Studies
Hematologic Neoplasms
Herpesvirus 4, Human
Histocompatibility Testing
Humans
Incidence
Lymphoproliferative Disorders
Male
Middle Aged
New York
Prognosis
Risk Factors
Rituximab
Survival Rate
Transplant Recipients
Transplantation Conditioning
Transplantation, Haploidentical
Virus Activation
Young Adult
authors with profiles
Koen Van Besien